×
Choose Speciality

EXPLORE!

LOGIN

By signing up or signing in to eMediNexus, you consent to eMediNexus collecting and using your personal data in accordance with our Privacy Policy. We are committed to safeguarding your information and ensuring the highest standards of data protection. Your trust and privacy are of utmost importance to us.

Study explores potential mechanisms behind decline in vascular events with empagliflozin

  904 Views

eMediNexus    03 February 2018

Data from a post-hoc analysis of the landmark EMPA-REG OUTCOME study show that changes in markers of plasma volume were the main factors causing a 38% decline in the risk of death due to vascular events with empagliflozin in patients with type 2 diabetes and established cardiovascular disease. These findings are published in the February 2018 issue of Diabetes Care.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.